8-K: Polomar Health Services to Merge with Altanine Inc., Announcing Major Leadership and Ownership Shifts

Polomar Health Services, Inc. has entered into a definitive merger agreement with Altanine Inc., which will result in Altanine becoming a wholly-owned subsidiary of Polomar and a significant shift in ownership and management.

Summary

• Polomar Health Services, Inc. (Polomar) has entered into an Agreement and Plan of Merger and Reorganization with Altanine Inc. (Altanine), under which Polomar Merger Sub, Inc. will merge into Altanine, with Altanine continuing as a wholly-owned subsidiary of Polomar.
• Each share of Altanine common stock will automatically convert into one share of Polomar common stock, and each share of Altanine preferred stock into one share of Polomar preferred stock, with fractional shares rounded up.
• Following the merger, former Altanine common stockholders are expected to own approximately 80% of the then-issued and outstanding shares of Polomar common stock, while current Polomar common stockholders are expected to own approximately 20%.
• Polomar agreed to assume Altanine's existing incentive plan, all outstanding options, and unexercised/unexpired warrants, adjusted by the Exchange Ratio.
• Polomar will also assume all unconverted and unexpired promissory notes of Altanine, with conversion terms adjusted for the Exchange Ratio.
• The merger is intended to constitute a tax-free reorganization for United States federal income tax purposes.
• The closing of the merger is subject to several conditions, including Polomar obtaining affirmative written consent from a supermajority of its disinterested stockholders (not yet obtained), regulatory approvals, SEC effectiveness of the S-4 Registration Statement, Nasdaq listing approval for the Surviving Company, Polomar effecting a reverse stock split to achieve a $10.00 per share price, and the completion of a concurrent financing of $7 million to $10 million.
• Polomar extended a professional services agreement with Profesco, Inc. and Terrence M. Tierney through August 31, 2025, for a flat fee of $64,000 plus reasonable approved expenses for the period April 1, 2025, through August 31, 2025.
• Polomar entered into a Promissory Note and Loan Agreement with Profesco Holdings, LLC (managed by Terrence M. Tierney) on July 28, 2025, allowing draws up to $100,000, with $72,528.50 already received. The note matures on October 31, 2025, or upon merger closing, with an initial interest rate of 12% APR.

Sentiment

Score: 4

Explanation: The merger offers strategic growth potential and capital infusion, but significant dilution for existing shareholders, the need for a reverse stock split, and pending stockholder approvals introduce considerable uncertainty and suggest a challenging current valuation. Related party transactions also add a layer of concern.

Positives

• The strategic merger with Altanine Inc. was unanimously approved by the boards of directors of both Polomar and Altanine, indicating strong internal alignment and commitment to the transaction.
• The transaction is structured as a tax-free reorganization under IRC 368(a)(2)(E), which is beneficial for tax purposes for the involved parties.
• Polomar's assumption of Altanine's existing incentive plan, outstanding options, and warrants suggests continuity and integration of Altanine's employee and investor base into the combined entity.
• The planned Equity Credit Line of at least $25 million and a Concurrent Financing of $7 million to $10 million indicate a significant capital injection and improved liquidity for the combined entity post-merger.
• The new board composition and management appointments, including Charles Andres, Jr. as CEO, suggest a refreshed leadership structure potentially bringing new strategic direction and expertise from Altanine.

Negatives

• Current Polomar common stockholders are expected to experience significant dilution, as they are projected to own only approximately 20% of the combined entity's common stock post-merger.
• The requirement for Polomar to effect a reverse stock split to achieve a stock price of $10.00 per share prior to closing indicates that the current stock price is below this threshold, which can be perceived as a negative signal regarding current market valuation.
• A critical closing condition, the affirmative written consent of a supermajority of Polomar's disinterested stockholders, has not yet been obtained as of the filing date, introducing uncertainty regarding the merger's completion.
• The Promissory Note and Loan Agreement with Profesco Holdings, LLC, where Terrence M. Tierney (Polomar's interim CEO, President, Secretary, and a director) is the sole member and manager, represents a related-party transaction that could raise corporate governance concerns.
• The extension of Terrence M. Tierney's professional services agreement through August 31, 2025, for a flat fee, while simultaneously announcing his resignation as interim CEO/President post-merger, creates a potential for perceived inefficiency or conflict in the leadership transition.

Risks

• Risk that Polomar and Altanine may not be able to complete the proposed Merger.
• Risk regarding the ability of the conditions to the closing of the transaction being timely satisfied.
• Risk concerning the ability of Polomar and/or Altanine to drive increased customer value and financial returns and enhance strategic and operational capabilities post-merger.
• Risk related to the ability to integrate the Altanine business into Polomar and realize the anticipated benefits of the transaction.
• Failure to obtain affirmative written consent of a supermajority of Polomar's disinterested stockholders.
• Failure to obtain approval of the Nasdaq Listing Application for the Surviving Company.
• Failure to effect a reverse stock split to achieve a $10.00 per share price prior to closing.
• Failure to complete the Concurrent Financing of at least $7 million.
• Any law or judgment prohibiting or making the Merger unlawful.
• Material breach of representations, warranties, or covenants by either party, which could lead to termination of the agreement.
• Other risks described under the headings 'Risk Factors' and 'Cautionary Statement Concerning Forward-Looking Statements' in Polomar's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other periodic SEC filings.

Future Outlook

The merger is intended to enhance strategic and operational capabilities and drive increased customer value and financial returns for the combined entity. Polomar will use its best efforts to secure a minimum $25 million Equity Credit Line and complete a $7 million to $10 million concurrent financing at $10.00 per share. The combined entity aims for Nasdaq listing.

Management Comments

• The board of directors of Polomar and of Altanine unanimously approved the Merger Agreement and the transactions contemplated thereby.
• The Parties intend that Altanine will be the accounting acquirer and Polomar will be legal acquirer in the Merger.
• The Merger is intended to constitute a reorganization within the meaning of Section 368(a)(2)(E) of the Internal Revenue Code of 1986.

Industry Context

The filing indicates a consolidation within the healthcare services sector, with Polomar acquiring Altanine. This suggests a strategy to expand market presence, enhance service offerings, or achieve economies of scale through inorganic growth. The focus on Nasdaq listing and capital raising indicates a move towards greater market visibility and financial stability, common in growing healthcare companies.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings are pending or threatened in writing against Polomar or Altanine that would result in a material adverse effect or challenge the merger, as per the representations and warranties.

Related Party Transactions

• Polomar Health Services, Inc. extended a Professional Services Agreement with Profesco, Inc. and Terrence M. Tierney (interim CEO, President, Secretary, and Director of Polomar) through August 31, 2025, for a flat fee of $64,000 plus expenses.
• Polomar Health Services, Inc. entered into a Promissory Note and Loan Agreement with Profesco Holdings, LLC, where Terrence M. Tierney is the sole member and manager. The note allows draws up to $100,000, with $72,528.50 already received by Polomar.

Stakeholder Impact

• Shareholders (Current Polomar): Expected to experience significant dilution, owning only approximately 20% of the combined entity post-merger, and potential negative impact from a required reverse stock split.
• Shareholders (Altanine): Expected to gain majority ownership (approximately 80%) of the combined entity, indicating a favorable outcome for their investment.
• Employees (Altanine): Altanine's existing incentive plan and outstanding options will be assumed by Polomar, providing continuity for employee equity.
• Management: Significant changes in executive leadership and board composition, with Altanine's CEO taking the helm of the combined entity and Altanine's appointees dominating the board.
• Creditors: Polomar will assume Altanine's unconverted and unexpired promissory notes, potentially increasing Polomar's debt obligations. The new $100,000 loan from a related party also impacts creditors.

Next Steps

• Polomar to obtain affirmative written consent of a supermajority of its disinterested stockholders.
• Polomar to file a Registration Statement on Form S-4 with the SEC, which must be declared effective.
• Polomar to prepare and submit a Nasdaq Listing Application for the Surviving Company and cause it to be approved.
• Polomar to effect a reverse stock split in order to achieve a stock price of $10.00 per share prior to Closing.
• Polomar to use its best efforts to enter into an Equity Credit Line in a minimum amount of $25 million.
• Polomar to adopt an amended Independent Director Compensation Policy.
• Completion of the Concurrent Financing of $7 million to $10 million.
• Altanine to deliver PCAOB compliant audited financial statements for fiscal years ending December 31, 2024 and 2023, and required unaudited financial statements.
• Closing of the Merger, expected no later than two business days after satisfaction or waiver of conditions.
• Polomar to file Current Reports on Form 8-K after execution of the Merger Agreement and the Closing Date.
• Polomar to prepare and file any necessary amendments or supplements to the S-4 Registration Statement.
• Altanine to hold a special meeting or seek written consent from its shareholders to approve the merger.

Key Dates

Recommendation

The merger with Altanine Inc. presents a strategic growth opportunity for Polomar Health Services, potentially expanding its market reach and operational capabilities, supported by planned capital raises. However, the substantial dilution for existing Polomar shareholders (reducing their ownership to 20%), the necessity of a reverse stock split (suggesting a low current valuation), and the pending supermajority stockholder approval introduce significant uncertainties and risks. The related-party transactions, while disclosed, warrant careful monitoring for potential conflicts of interest. Given the mix of strategic positives and considerable execution risks and dilution, a 'hold' recommendation is appropriate until further clarity emerges on the merger's completion, the impact of the reverse stock split, and the integration process.

Keywords

Merger, Acquisition, Healthcare Services, Corporate Governance, SEC Filing, 8-K, Stock Split, Capital Raise, Dilution, Related Party Transaction, Nasdaq Listing, Financial Reporting, Altanine, Polomar Health Services